Amarna Therapeutics and NorthX Biologics Advance Nimvec™ AM510 Gene Therapy Towards Clinical Trials for Type 1 Diabetes
Wednesday, July 09, 2025
Amarna Therapeutics, a biotechnology company focused on gene therapies, has finalised an agreement with NorthX Biologics to accelerate the development of its gene therapy platform, Nimvec™. The partnership aims to prepare Nimvec™ AM510, a treatment candidate for Type 1 Diabetes, for future clinical trials.
This agreement builds on a partnership established in the previous year, which began the process of transferring Amarna’s research-scale production of Nimvec™ AM510 to NorthX Biologics’ advanced facilities. NorthX Biologics is a contract development and manufacturing organisation (CDMO) specialising in biologics.
Nimvec™ AM510 is designed to address the root cause of Type 1 Diabetes by restoring immune tolerance to insulin-producing beta cells. The therapy targets proinsulin — a key trigger in the autoimmune response that leads to the destruction of beta cells — aiming to prevent further damage.
As part of the agreement, Amarna will transfer and refine its production process for AM510 to support larger-scale, clinical-grade manufacturing. The development includes analytical tools to monitor the therapy's identity, potency, and quality during its lifecycle.
The collaboration combines Amarna’s proprietary Nimvec™ technology with NorthX’s manufacturing expertise to establish a scalable, regulatory-ready production platform. This is a crucial step in moving Nimvec™ AM510 closer to human trials, which are currently planned for 2027.
In addition to supporting AM510, the agreement also lays the groundwork for the production of future Nimvec™-based therapies aimed at other immune-mediated and inflammatory diseases.
This development highlights both companies’ commitment to advancing next-generation gene therapies through reliable and scalable manufacturing solutions.
Source: globenewswire.com
